These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 30953541)

  • 21. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation.
    de Vries MK; Wolbink GJ; Stapel SO; de Vrieze H; van Denderen JC; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
    Ann Rheum Dis; 2007 Sep; 66(9):1252-4. PubMed ID: 17472991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.
    Rahman P; Choquette D; Bensen WG; Khraishi M; Chow A; Zummer M; Shaikh S; Sheriff M; Dixit S; Sholter D; Psaradellis E; Sampalis JS; Letourneau V; Lehman AJ; Nantel F; Rampakakis E; Otawa S; Shawi M
    BMJ Open; 2016 Apr; 6(4):e009661. PubMed ID: 27048632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.
    Tweehuysen L; van den Bemt BJF; van Ingen IL; de Jong AJL; van der Laan WH; van den Hoogen FHJ; den Broeder AA
    Arthritis Rheumatol; 2018 Jan; 70(1):60-68. PubMed ID: 29045077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis.
    Baraliakos X; Listing J; Rudwaleit M; Brandt J; Alten R; Burmester G; Gromnica-Ihle E; Haibel H; Schewe S; Schneider M; Sörensen H; Zeidler H; Visvanathan S; Sieper J; Braun J
    J Rheumatol; 2007 Mar; 34(3):510-5. PubMed ID: 17299842
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N; Kong KO; Tennant A; Fraser A; Hensor E; Keenan AM; Emery P
    Rheumatology (Oxford); 2005 Oct; 44(10):1277-81. PubMed ID: 16105913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update.
    Pham T; Fautrel B; Dernis E; Goupille P; Guillemin F; Le Loët X; Ravaud P; Claudepierre P; Miceli-Richard C; de Bandt M; Breban M; Maillefert JF; Masson C; Saraux A; Schaeverbeke T; Wendling D; Mariette X; Combe B;
    Joint Bone Spine; 2007 Dec; 74(6):638-46. PubMed ID: 18065252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab in two patients with juvenile ankylosing spondylitis.
    Schmeling H; Horneff G
    Rheumatol Int; 2004 May; 24(3):173-6. PubMed ID: 14648110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of tumor necrosis factor inhibitor on serum level of HLA-B27 and PDCD-1 in patients with ankylosing spondylitis.
    Chen X; Zhou X; Li X; Tang J; Hu X; Wang J; Xu C
    Cell Biochem Biophys; 2014 Nov; 70(2):1453-7. PubMed ID: 25005770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.
    Arends S; van der Veer E; Kamps FB; Houtman PM; Bos R; Bootsma H; Brouwer E; Spoorenberg A
    Clin Exp Rheumatol; 2015; 33(2):174-80. PubMed ID: 25797228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials.
    Baraliakos X; Koenig AS; Jones H; Szumski A; Collier D; Bananis E
    J Rheumatol; 2015 Aug; 42(8):1418-26. PubMed ID: 26077401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry.
    Glintborg B; Ostergaard M; Krogh NS; Dreyer L; Kristensen HL; Hetland ML
    Ann Rheum Dis; 2010 Nov; 69(11):2002-8. PubMed ID: 20511613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
    Závada J; Uher M; Sisol K; Forejtová Š; Jarošová K; Mann H; Vencovský J; Pavelka K
    Ann Rheum Dis; 2016 Jan; 75(1):96-102. PubMed ID: 25165033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.
    Ertenli I; Ozer S; Kiraz S; Apras SB; Akdogan A; Karadag O; Calguneri M; Kalyoncu U
    Rheumatol Int; 2012 Feb; 32(2):323-30. PubMed ID: 21079965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study.
    Lubrano E; Massimo Perrotta F; Manara M; D'Angelo S; Addimanda O; Ramonda R; Punzi L; Olivieri I; Salvarani C; Marchesoni A
    J Rheumatol; 2016 Aug; 43(8):1541-6. PubMed ID: 27252428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis.
    Caso F; Costa L; Del Puente A; Rigante D; Selmi C; Fabbroni M; Scarpa R; Galeazzi M; Frediani B; Cantarini L
    Clin Exp Rheumatol; 2015; 33(3):411-3. PubMed ID: 25962691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.